Publications by authors named "M Reano-Martos"

Introduction: The prevalence of asthma in adults >65 years old is approximately 12-14%, and 10% have severe asthma. A higher mortality rate is observed in subjects with asthma >65 years old and especially >80 years old.

Objective: To analyze the effectiveness and safety of at least three doses of benralizumab in a subgroup of elderly subjects (>65 years old) with uncontrolled severe eosinophilic asthma in real-life conditions.

View Article and Find Full Text PDF

The resolution of inflammation is a complex process that is critical for removing inflammatory cells and restoring tissue function. The dysregulation of these mechanisms leads to chronic inflammatory disorders. Platelets, essential cells for preserving homeostasis, are thought to play a role in inflammation as they are a source of immunomodulatory factors.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to improve the collection of high-quality platelet samples for immunological research by using a protocol based on plateletpheresis.
  • The researchers obtained Platelet-Rich Plasma (PRP), Platelet-Poor Plasma (PPP), and isolated CD3 and CD14 cells from a single donation, which provides matched samples for analysis.
  • The method successfully yielded pure platelet samples necessary for RNA and protein studies, confirming that they can be utilized for transcriptomic research despite initial challenges with RNA quality assessment.
View Article and Find Full Text PDF

Introduction: The increase in drugs available for severe uncontrolled asthma and the lifestyle of these patients make it necessary to implement self-administration programs of these therapies at home. Benralizumab, a monoclonal antibody targeting IL5R, was authorized in Spain for poorly controlled severe eosinophilic asthma. The possibility of administration at home was approved in March 2020 in Spain.

View Article and Find Full Text PDF

Background And Objective: Allergen immunotherapy clinics (AITCs) in Spain differ widely in terms of structure, organization, resources, and portfolio of services. Therefore, it is essential to unify treatment criteria and define quality standards for the most complex AITCs. Objective: To establish a series of recommendations that make it possible to guarantee quality and safety in the administration of immunotherapy and define quality standards for the most complex AITCs.

View Article and Find Full Text PDF